News Bad week for dementia R&D after Axovant howler and another f... Axovant misreports trial results, Lundbeck Alzheimer's drug fails
News A Pfizer consumer buyout won't detract from pharma business,... Walmsley has axed 40% of management team in shake-up
News Pfizer axes Alzheimer's and Parkinson's research Big pharma will continue developing tanezumab painkiller with Lilly
News Novartis taking aim at Pfizer with new use for breast cancer... FDA grants Breakthrough Therapy for Kisqali in premenopausal women.
News Merck/Pfizer undercut rivals with newly approved diabetes dr... Steglatro cheaper than SGLT2 rivals from AZ and Lilly/Boehringer
News NICE to reassess Pfizer blood cancer drug Company successfully appealed against rejection last summer
News Angelini Pharma's R&D chief heads for the exit Dr Rafal Kaminski's near five-year tenure as chief scientific officer of Italy's Angelini Pharma will come to an end in the next couple of weeks.
Sales & Marketing Sponsored Securing your ROI: Turning post-acquisition integration into... Join Forinnovia and Little Cube Consulting for a webinar on securing post-acquisition ROI.